• Immunosuppressive therapy

  • Immunosuppressive therapy

  • Immunosuppressive therapy

#Immunosuppression #Middle East

Live Session:

Thursday, July 1, 2021 - 2:00 PM (Local time in Beirut)
Local time (Corresponding local time at your current location)

Join us:



The quest for a fixed-dose immunosuppressive drug has not yet materialized.  We have learned over the years that the dose and or blood levels correlate poorly with the clinical events. It was also clear that there are intra and inter-patient pharmacokinetic variabilities blood trough levels and area under the curve (AUC) for all maintenance therapy.  It is also important to recognize that in many centers multi organs are being transplanted in adults, pediatrics and the immunocompromised recipient which necessitate different immunosuppressive protocols. This led many centers to establish their own immunosuppressive protocols from induction therapy, maintenance therapy as well as allograft rejection therapy. In this class, the two speakers will address these issues.


Immunosuppressive therapy in the sensitized patients

Jeremy Chapman

Clinical Professor
Medicine, Westmead Clinical School
The Westmead Institute for Medical Research
Sydney, Australia

Professor Jeremy R. Chapman is a nephrologist based in Sydney Australia, with research interests in preclinical and clinical research in kidney, pancreas, bone marrow, and islet transplantation. He is the Editor-in-Chief for Transplantation and Transplantation Direct 2015-2023, a Past-President of The Transplantation Society, Advisory Member of The World Health Organisation Expert Advisory Panel on Human Cell Tissue and Organ Transplantation, Secretary-General and Past President of the World Marrow Donor Association, founding Co-Chair of the Declaration of Istanbul Custodian Group, Chairman of the Australian Bone Marrow Donor Registry, the Australian Cord Blood Bank Network, and Past President of the Transplantation Society of Australia and New Zealand. He chairs the Vigilance and Safety committee of the Australian Organ and Tissue Authority. He received the Asturias Foundation 2010 Award for International Cooperation on behalf of The Transplantation Society and was awarded the 2010 David Hume Award of the US National Kidney Foundation. He was awarded the Medal of the Order of Australia in 2003 (OAM) and Companion of the Order of Australia in 2015


Personalized immunosuppression: is it justified?

Hassan Argani

Transplant Consultant, Shahid Beheshti University 
Director of Clinical Pharmacy, Drug Applied Research Center (DARC), Tabriz University 
Tehran, Iran

Dr. Argani is Professor of Nephrology at the Shahid Beheshti University of Medical Sciences. His main interests are renal transplantation and immunosuppressive drugs. Dr. Argani has published over 110 papers in international journals and presented at over 100 international congresses.

He is a transplant Consultant in the Shahid Beheshti University of Medical Sciences and Director of Clinical Pharmacy of Drug Applied Research Center (DARC) at Tabriz University of Medical Sciences.

Dr. Argani is a Member of multiple associations, including the American Society of Nephrology, the International Society of Nephrology, the European Dialysis and Transplant Association, and the Middle East Society of Organ Transplant.

He is the immediate past secretary of CKD committee of the Urology and Nephrology Research Center (UNRC) at Shahid Beheshti University of Medical Sciences and the Editorial Board of the Iranian Society of Nephrology.

Dr. Argani is the current vice president of the Middle East Society of Organ Transplantation and has also held several leadership positions in the society. He is immediate past chairman of the education committee; past councilor on behalf of Iran and past General Secretary.

Schedule (90 min):

  • 05 min

    Welcome and introduction by the Chair
  • 25 min

    Presentation: Immunosuppressive therapy in the sensitized patients, Jeremy Chapman, Australia

  • 05 min

    Live Q&A with Jeremy Chapman, Australia

  • 25 min

    Presentation: Personalized immunosuppression: is it justified?, Hassan Argani, Iran

  • 05 min

    Live Q&A with Hassan Argani, Iran

  • 20 min

    Interactive panel discussion with audience participation led by the Chair
  • 05 min

    Masterclass closing remarks

Join Our Mailing List

Ask a Question

Masterclass Prospectus Request